Chinese API producers shielded from medium-term pain despite COVID-19-related market rebalancing: Fitch Ratings
Reducing dependence on China would increase production costs for generic drug makers, analysts say
Chinese active pharmaceutical ingredient manufacturers are unlikely to suffer any medium-term effects from increasing trade protectionism and buyers’ moves to diversify their supply amid the COVID-19 pandemic, but those with high exposure to India could lose business due to the country’s initiatives to reduce reliance on Chinese production, according to analysts at Fitch Ratings.
In the report ‘No Near-Term Impact on Chinese API Makers as Pharma Supply-Chain Shifts,’ the company said China's API production has recovered earlier than global peers' as business activities are returning to normal following the lifting of quarantines to stop the spread of COVID-19.
“Hence, it is better positioned to capture the increased drug demand generated by the outbreak, as well as demand redirected from overseas markets that have halted production,” Fitch said.
Major Chinese API manufacturers have reported strong sales in Q1, with Shenzhen Hepalink Pharmaceutical Group and Zhejiang Huahai Pharmaceutical seeing their respective revenue increase by 37.1% and 31% year-on-year, versus growth of 6.7% and decline of 3.2% in Q1 2019.
Fitch said supply-chain disruptions caused by the coronavirus have led to China’s two largest export markets for APIs taking measures to reduce their exposure.
The US is calling for pharmaceutical companies to reduce purchases of APIs from China and move API production back on a domestic footing amid drug supply shortages, while India - the world's largest generic drug producer - has announced a USD1.3 billion investment in domestic API production to reduce its Chinese imports, which account for nearly 70% of India's API demand.
“We do not believe this rebalancing will result in a significant change in China's role in the global drug supply chain in the medium term,” Fitch said. “Sourcing less from China would increase production costs, especially for generic drug makers, for whom APIs are a significant portion of costs. In addition, China's dominance in APIs means substitutes are probably not available in the near term. China is the major supplier of raw materials for certain drugs, such as antibiotics and vitamins.”
The report added that India's recently announced domestic API production enhancement plan – which involves the establishment of drug-manufacturing industrial parks to support the output of 53 key APIs -- might take years for production to ramp up.
“There are still uncertainties over India's API production ramp-up as this will depend on price competitiveness of local production once further clarity on the government incentives emerges. As such, the impact is unlikely to be seen in the near term,” the report said.
The Fitch analysts said they believed Chinese API makers with high drug quality and diversified product portfolios that include speciality APIs are better positioned to cope with the long-term challenges arising from the coronavirus-led supply-chain rebalancing.
“The trend will also prompt Chinese API makers to increase R&D spending and improve manufacturing technology to maintain their competitiveness against rivals,” they concluded.
India and the US accounted for 16.8% and 12.5% of China's total API export value, respectively, in 2019.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance